Stentys Appoints René Spaargaren, MD, as
Chief Medical Officer
ev3’s former Vice President of
International Clinical Affairs will oversee clinical development of
Stentys’ stent for treatment of blocked
coronary artery bifurcations
“Dr. Spaargaren’s
extensive experience in leading the clinical development of
cardiovascular technologies while working for companies such as ev3,
Boston Scientific and Medtronic will certainly fortify our ongoing
clinical development efforts.”
Gonzague Issenmann, Co-Founder and CEO, Stentys
PARIS (Business Wire EON/PRWEB ) September 3, 2008 --
Stentys (http://www.stentys.com)
announced today that it has appointed Dr. René
Spaargaren as its Chief Medical Officer (CMO). Stentys is developing
the world’s
first next-generation drug-eluting stent for treatment of
blocked coronary artery bifurcations so that hundreds of
thousands of patients might avoid open-chest surgery.
Previously at ev3, Dr. Spaargaren was Vice President of International
Clinical Affairs since 2002, where he was responsible for driving new
product development from R&D to acceptance by the medical community and
launch into international markets. Prior to ev3, Dr. Spaargaren served
for seven years (1995-2002) with Boston Scientific Corp. as Medical
Director, Europe; and for three years (1992-1995) as Clinical Manager,
Europe, with Medtronic (Cardiac Assist Venture).
“Dr. Spaargaren has achieved a great deal of
success over the past six years at ev3 in helping the company establish
itself as a market leader in several fast-growing vascular
market-segments,” said Stentys’
CEO and co-founder, Gonzague Issenmann. “No
doubt, he will play a critically important role in helping to establish
that the Stentys bifurcation stent is as easy for cardiologists to use
as conventional stents—but that our
bifurcation stent is designed to provide superior treatment options by
enabling full opening of the side branch.”
Coronary artery disease is caused by fatty lesions that narrow the
coronary artery’s inside diameter (stenosis),
consequently reducing the blood flow and depriving the heart muscle of
oxygen. The dramatic consequence of this blockage is an often-lethal
myocardial infarction (heart attack). Bifurcation is the area where one
main vessel branches out into two smaller vessels, one being the
continuation of the main vessel, and the other often referred to as the
side branch. Narrowings at a bifurcation site are quite common. Indeed,
18 percent of percutaneous coronary interventions involve a bifurcation
stenosis. Of those, restenosis (re-occurrence of the blockage) occurs in
20-25 percent of bifurcations treated with drug-eluting stents (DES).
The patent-pending innovation of Stentys’
bifurcated stent is that the stent-opening for the side branch can be
created anywhere in the stent after it is implanted in the vessel. In
short, the procedure’s success is independent
from accurate positioning. The Stentys procedure is performed in three
simple steps: (1) Stentys is implanted in the main vessel with an
approximate positioning, like a standard stent; (2) the cardiologist
chooses the optimal location for the side branch opening by inserting a
balloon through the stent mesh, which is a cath lab-standard procedure;
and, (3) the balloon inflation disconnects the mesh and creates the
opening—Stentys’
self-expanding property allows the in situ modeling of the stent to fit
the patient’s unique arterial anatomy.
About Stentys
Based in Paris, Stentys intends to make treatment of blocked coronary
artery bifurcations as simple and effective as a conventional stenting
procedure. The Company has developed the world’s
first next-generation dedicated stent for treatment of blocked
coronary artery bifurcations that is designed so that hundreds of
thousands of patients might avoid open-chest surgery. To date, the
Stentys bifurcated stent has been successfully implanted in patients as
part of the OPEN 1 trial, taking routine interventional time to
complete; the patients were released from the ICU within hours of
implantation of the Stentys bifurcated stent and were discharged from
the hospital shortly after the procedure.
MULTIMEDIA GALLERY http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5769227
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3F1YS1JbnNlLVNpbmctTG92ZS1QaWdnLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.